DeepScan Diagnostics
DeepScan Diagnostics is a Helsinki-based veterinary diagnostics company founded in 2024 that develops a proprietary liquid biopsy blood test (CFD®) using circulating cell-free DNA and machine learning to detect cancer and monitor diseases in dogs through partner veterinary clinics.
- Company typePrivate
- Founded2024
- HeadquartersHelsinki, Finland
- Headcount11–50
- GTM typeB2B
- OfferingServices
What DeepScan Diagnostics does
DeepScan Diagnostics is a Helsinki-based veterinary diagnostics company founded in 2024 that develops and commercializes the proprietary CFD® (Circulating cell-free DNA) biomarker platform for canine disease detection. The company's core product is a liquid biopsy blood test that analyzes cfDNA in canine samples to enable early cancer detection, disease monitoring, and treatment efficacy assessment in dogs. The technology integrates multimodal analysis of fragment size, mutations, copy number variations, and methylation patterns, processed through machine learning algorithms trained on a proprietary dataset of 5,000+ validated samples.
The business model operates on a B2B2C basis, partnering with veterinary clinics that offer the CFD® test to pet owners as part of their diagnostic workflow. The company has established partnerships with clinics in Finland (Pieni Eläinsairaala, LiVet, SoVet, Abbis) and has begun US expansion through a partnership with Sploot Veterinary Care in Colorado. An in-house diagnostic laboratory was opened in Helsinki in October 2025 to internalize sample processing and scale test capacity. The company has raised approximately $5.5M in total funding (€2M pre-seed in November 2024 and $3.5M in April 2026) and operates with a team of approximately 15 employees, including PhD-level scientists and a dedicated Head of Data Science. Pricing model details are not publicly disclosed, but the product is positioned as a premium molecular diagnostic offering for veterinary care.
DeepScan Diagnostics firmographics
Firmographics- Name
- DeepScan Diagnostics
- Legal name
- DeepScan Diagnostics
- Website
- https://deepscandx.com
- Company type
- Private
- Founded year
- 2024
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- DeepScan Diagnostics is a Helsinki-based veterinary diagnostics company founded in 2024 that develops a proprietary liquid biopsy blood test (CFD®) using circulating cell-free DNA and machine learning to detect cancer and monitor diseases in dogs through partner veterinary clinics.
- Ownership category
- akta.pro rank
DeepScan Diagnostics industry classification
Industry- Product category
- Veterinary Diagnostics
- NAICS
- Medical Laboratories (621511), Medical and Diagnostic Laboratories (62151)
- SIC
- Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- Molecular & Genetic Testing (Breed, Hereditary Disease, Oncology) (HLAMADAE)
- akta.pro secondary industries
- Reference Laboratory Testing (Clinical Pathology & Chemistry) (HLAMADAA), Laboratory & Point-of-Care Diagnostic Devices (Analyzers, Test Kits, Microscopy) (HLAMAFAI)
Keywords
Where DeepScan Diagnostics is headquartered
LocationHeadquarters
- HQ city
- Helsinki
- HQ country
- Finland
- HQ region
- Europe
Offices2 records
Markets served
DeepScan Diagnostics business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- Diagnostic Testing Services: DeepScan provides cfDNA-based diagnostic testing services to veterinary clinics, offering CFD biomarker tests for early disease detection in dogs. Tests are ordered through veterinary practices and processed in DeepScan's laboratory.
Go-to-market motion2 records
Distribution channels3 records
Marketing channels5 records
DeepScan Diagnostics product offering
Product offeringCore offering
DeepScan Diagnostics provides a cfDNA-based liquid biopsy blood test (CFD® Biomarker) for dogs, designed for use by veterinary clinics. The test measures circulating cell-free DNA levels in canine blood to support early disease detection, cancer screening, treatment monitoring, and disease severity assessment. Samples are processed in DeepScan's Helsinki laboratory, with results returned to the ordering veterinary clinic.
Product overview
DeepScan Diagnostics offers a single core diagnostic product: the CFD® (Circulating cell-free DNA) biomarker test. This liquid biopsy blood test analyzes cfDNA levels to help veterinarians detect and monitor disease earlier in dogs. The company has built an extensive scientific validation library with over 5,000 validated samples and multiple pilot studies demonstrating applications across oncology, acute pancreatitis, hepatotoxicity, splenic disease, and lymphoma remission monitoring. The technology platform combines molecular biology analysis, next-generation sequencing, and machine learning algorithms for diagnostic predictions.
Differentiator
Problem solved
Functional benefit
Products and services
- CFD® Biomarker (Circulating cell-free DNA Diagnostics) A liquid biopsy blood test that measures circulating cell-free DNA (cfDNA) levels in dogs, enabling early disease detection, cancer screening, treatment efficacy monitoring, and disease severity assessment for veterinary clinics. Tests are ordered through veterinary clinics, which collect blood samples, ship processed plasma to DeepScan's Helsinki laboratory, and receive results back for clinical decision-making.
Quantifiable outcome
- Validated across 5,000+ samples for reproducibility and clinical utility
- +1 more outcomes
Companies that use DeepScan Diagnostics
Customer profileNamed customers5 records
Segments2 records
Ideal customer profiles1 record
DeepScan Diagnostics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability4 records
Feature3 records
DeepScan Diagnostics partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered core and minor.
- AbbiscoreDeepScan and Abbis partnered to bring preventive cfDNA testing to Finnish pet parents, expanding the availability of early disease detection services in Finland through Abbis's distribution network.
- Sploot Veterinary CarecoreDeepScan partnered with Sploot Veterinary Care to launch the CFD test in Colorado, USA. This partnership expands access to DeepScan's cfDNA-based diagnostics in the US market and supports clinics in integrating minimally invasive testing into routine care.
- Pieni EläinsairaalaminorFinnish veterinary clinic partner offering DeepScan's CFD diagnostic testing services to pet owners.
- LiVetminorFinnish veterinary clinic partner offering DeepScan's CFD diagnostic testing services.
- SoVetminorFinnish veterinary clinic partner offering DeepScan's CFD diagnostic testing services.
Scale indicators4 records
Recent moves7 records
Expansion highlights5 records
DeepScan Diagnostics competitors and assessment
Company assessmentDirect peers
- Wisdom Panel: Canine and feline genetic testing brand owned by Mars Petcare, offering breed and health screening using DNA. Comparable as a canine DNA diagnostics brand with established veterinary and consumer channels.
- Embark Veterinary: Dog-focused genetic testing company using DNA-based diagnostics for breed, health risk, and trait information. Comparable as a canine-focused molecular diagnostics company selling advanced DNA tests directly to dog owners and through veterinarians.
- PetDx: US-based canine liquid biopsy company offering cfDNA-based cancer detection in dogs using next-generation sequencing. The most direct technology and product overlap with DeepScan's CFD biomarker in the canine oncology diagnostics space.
Broad incumbents
- Ceva Animal Health: Global animal health company providing pharmaceuticals, vaccines, and diagnostics across companion and production animal segments. Comparable as a broader animal health player with companion-animal diagnostics ambitions.
- Antech Diagnostics: Veterinary reference laboratory network owned by Mars Petcare, providing a wide menu of diagnostic tests to companion animal practices across North America. Comparable as a centralised laboratory serving clinics, similar distribution model to DeepScan.
- IDEXX Laboratories: Largest pure-play veterinary diagnostics company, offering reference lab services, in-clinic analyzers, and a broad menu of tests. Deeply embedded in companion animal clinics globally, with the infrastructure to distribute competing diagnostic tests if it chooses to enter cfDNA.
- Zoetis: Global animal health company with a growing diagnostics portfolio (Vetscan, reference labs) and direct relationships with veterinary practices. Represents a large incumbent that could bundle or compete with novel molecular diagnostics.
- Heska (Mars Petcare): Veterinary diagnostics company acquired by Mars Petcare, offering in-clinic and reference-lab testing. Comparable as an established diagnostics provider with broad clinic reach that could expand into molecular liquid biopsy.
Others
- Guardant Health: Human-focused liquid biopsy and cfDNA testing company at scale in oncology. Comparable as a technology adjacency - the underlying cfDNA analytics and reference lab methodology are directly transferable to veterinary applications.
Emerging players
- Vidium Animal Health: Veterinary molecular diagnostics company translating human precision medicine into animal health, with focus on oncology. Comparable as an emerging player applying advanced molecular testing to companion animal cancer.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks5 records
Key highlights6 records
Customer concentration
DeepScan Diagnostics social profiles
Digital presenceDeepScan Diagnostics compliance and trust
Trust signalCompliance1 record
DeepScan Diagnostics financial estimates
Financial estimateRevenue estimate
Valuation estimate
DeepScan Diagnostics leadership team
Management profileNumber of profiles
Profiles11 records
DeepScan Diagnostics funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
DeepScan Diagnostics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about DeepScan Diagnostics
What does DeepScan Diagnostics do?
DeepScan Diagnostics provides a cfDNA-based liquid biopsy blood test (CFD® Biomarker) for dogs, designed for use by veterinary clinics. The test measures circulating cell-free DNA levels in canine blood to support early disease detection, cancer screening, treatment monitoring, and disease severity assessment. Samples are processed in DeepScan's Helsinki laboratory, with results returned to the ordering veterinary clinic.
Is DeepScan Diagnostics a public or private company?
DeepScan Diagnostics is a private company. It is classified as venture growth investor backed and is currently operating.
When was DeepScan Diagnostics founded?
DeepScan Diagnostics was founded in 2024. It employs 11 to 50 people.
Where is DeepScan Diagnostics based?
DeepScan Diagnostics is headquartered in Helsinki, Finland, in the Europe region.
How does DeepScan Diagnostics make money?
One revenue line is on record: diagnostic Testing Services.
Who are DeepScan Diagnostics's main competitors?
Direct peers on record are Wisdom Panel, Embark Veterinary and PetDx. Broad incumbents are Ceva Animal Health, Antech Diagnostics, IDEXX Laboratories, Zoetis and Heska (Mars Petcare). Guardant Health is listed as an others. Vidium Animal Health is listed as an emerging player.
Does DeepScan Diagnostics have an API?
No public API is recorded for DeepScan Diagnostics.
What industry is DeepScan Diagnostics in?
DeepScan Diagnostics's product category is Veterinary Diagnostics. Its primary akta.pro industry code is HLAMADAE, Molecular & Genetic Testing (Breed, Hereditary Disease, Oncology), with a secondary code of HLAMADAA, Reference Laboratory Testing (Clinical Pathology & Chemistry). Its NAICS code is 621511 and its SIC code is 8071.